| Trial ID: | L0319 |
| Source ID: | NCT01351636
|
| Associated Drug: |
Arotinolol Hydrochloride
|
| Title: |
Effect of Arotinolol Hydrochloride on Cardiovascular Events in Hypertensive Haemodialysis Patients
|
| Acronym: |
AHOCEP
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Chronic Kidney Disease
|
| Interventions: |
DRUG: Arotinolol Hydrochloride|DRUG: Non arotinolol group
|
| Outcome Measures: |
Primary: Composite endpoints, 18 months | Secondary: Changes for metabolism related index, 18 months|Blood pressure control in hypertensive haemodialysis patients, 18 months
|
| Sponsor/Collaborators: |
Sponsor: Sumitomo Pharma (Suzhou) Co., Ltd.
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE4
|
| Enrollment: |
300
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2011-04
|
| Completion Date: |
2018-10-10
|
| Results First Posted: |
|
| Last Update Posted: |
2019-04-17
|
| Locations: |
Nan Chen, Shanghai, Shanghai, 200025, China
|
| URL: |
https://clinicaltrials.gov/show/NCT01351636
|
